Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Treatment-Resistant Major Depression
NCT07052058Phase 2Not yet recruiting
- Sponsor
- Hospital de Clínicas de Porto Alegre
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in major depressive disorder (MDD), sponsored by Hospital de Clínicas de Porto Alegre. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
tocilizumab
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07052058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07052058.